PRESS RELEASE published on 07/03/2024 at 08:12, 1 year 9 months ago CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities CureVac initiates strategic restructuring to focus on high-value mRNA pipeline opportunities, including workforce reduction and new GSK agreement Oncology Strategic Restructuring CureVac MRNA Pipeline GSK Agreement
PRESS RELEASE published on 07/03/2024 at 08:09, 1 year 9 months ago GSK and CureVac to Restructure Collaboration into New Licensing Agreement GSK and CureVac restructure collaboration into new licensing agreement for mRNA vaccines development, manufacturing, and commercialization globally Licensing Agreement Collaboration GSK MRNA Vaccines CureVac
BRIEF published on 06/24/2024 at 22:10, 1 year 9 months ago CureVac Announces Voting Results of General Meeting Annual General Meeting Voting Results Board Appointments CureVac MRNA
PRESS RELEASE published on 06/24/2024 at 22:05, 1 year 9 months ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of the general meeting, including board appointments and auditor reappointment. Shareholders voted in favor of all proposals Appointments Voting Results General Meeting CureVac Auditor Reappointment
BRIEF published on 05/28/2024 at 13:05, 1 year 10 months ago CureVac Announces Dosing of First Participant in Phase 2 Influenza Study GSK MRNA Technology Phase 2 Study CureVac Influenza Vaccine
PRESS RELEASE published on 05/28/2024 at 13:00, 1 year 10 months ago CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK CureVac initiates Phase 2 study in collaboration with GSK for seasonal influenza vaccine, targeting improved immune responses against influenza B strain GSK Vaccine Development Phase 2 Study CureVac Seasonal Influenza
BRIEF published on 05/23/2024 at 13:05, 1 year 10 months ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update Financial Results Business Update Q1 2024 CureVac FDA Fast Track
PRESS RELEASE published on 05/23/2024 at 13:00, 1 year 10 months ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update CureVac announces financial results for Q1 2024, reports €300.2 million cash position and updates on organizational restructuring and patent litigations Financial Results Cash Position CureVac Patent Litigation Organizational Redesign
BRIEF published on 04/24/2024 at 13:11, 1 year 11 months ago CureVac Announces 2023 Financial Results and Strategic Business Updates MRNA Technology CureVac Pharmaceutical Collaborations Oncology Vaccines Prophylactic Vaccines
BRIEF published on 04/24/2024 at 13:08, 1 year 11 months ago CureVac Begins Combined Phase 1/2 Study for Avian Influenza H5N1 Vaccine with GSK GSK CureVac Phase 1/2 Study Influenza H5N1 MRNA Vaccine
Published on 04/11/2026 at 02:00, 1 day ago Lobe Sciences Ltd. Announces Non-Brokered Private Placement
Published on 04/11/2026 at 01:40, 1 day 1 hour ago Arctic Fox Announces Closing of Final Tranche Of Non-Brokered Private Placement
Published on 04/11/2026 at 00:30, 1 day 2 hours ago Trans Canada Gold Corp. Announces Proposed Warrant Extension
Published on 04/11/2026 at 16:45, 10 hours 6 minutes ago CGTN: One family: Xi Jinping stresses keeping future of cross-Strait ties in Chinese hands
Published on 04/11/2026 at 16:40, 10 hours 11 minutes ago VARON Delivers Advanced Portable Oxygen Concentrator to Meet Rising Demand in Europe
Published on 04/11/2026 at 16:30, 10 hours 21 minutes ago VARON Oxygen Concentrators Meet Rising Demand for Modern Oxygen Therapy in Germany
Published on 04/10/2026 at 19:00, 1 day 7 hours ago EPIC Suisse AG – Annual General Meeting 2026 approves all proposals by the Board of Directors
Published on 04/11/2026 at 16:29, 10 hours 22 minutes ago Passing of Madame Jacqueline Himsworth, Chairman of the Board of Directors of Manitou Group
Published on 04/10/2026 at 18:26, 1 day 8 hours ago EURAZEO ANNOUNCES THE SUCCESS OF ITS INAUGURAL 500 MILLION EURO BOND ISSUE
Published on 04/10/2026 at 18:00, 1 day 8 hours ago Declaration of voting rights at the end of March 2026
Published on 04/10/2026 at 17:45, 1 day 9 hours ago Imerys-10-04-2026-implementation of the share buyback program
